Volition (1)

Corporate Presentation 公司报告

May 2021 2021年5月




Forward Looking Statements and Disclaimer 前瞻性陈述与免责声明

Statements in this document may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as "expects," "anticipates," "intends," "plans," "aims," "targets," "believes," "seeks," "estimates," "optimizing," "potential," "goal," "suggests," "could," "would," "should," "may," "will" and similar expressions identify forward-looking statements. These forwardlooking statements relate to the timing, completion and delivery of data from clinical studies, the effectiveness of Volition's blood-based diagnostic and prognostic tests as well as Volition's ability to develop and successfully commercialize such test platforms for early detection of cancer and other diseases as well as serving as a diagnostic or prognostic tool for COVID-19. Volition's actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties, including, without limitation, results of studies testing the efficacy of its tests. For instance, if Volition fails to develop and commercialize diagnostic or prognostic products, it may be unable to execute its plan of operations. Other risks and uncertainties include Volition's failure to obtain necessary regulatory clearances or approvals to distribute and market future products; a failure by the marketplace to accept the products in Volition's development pipeline or any other diagnostic or prognostic products Volition might develop; Volition's failure to secure adequate intellectual property protection; Volition will face fierce competition and Volition's intended products may become obsolete due to the highly competitive nature of the diagnostics market and its rapid technological change; downturns in domestic and foreign economies; and other risks identified in Volition's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that Volition files with the Securities and Exchange Commission. These statements are based on current expectations, estimates and projections about Volition's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this release, and, except as required by law, Volition does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.

Nucleosomics[™] and Nu.Q[®] and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release are the property of their respective owners. Additionally, unless otherwise specified, all references to "\$" refer to the legal currency of the United States of America.

Investment Highlights

投资亮点



Broad intellectual property portfolio, including 64 granted patents to date worldwide广泛的知识产权组合,包括迄今为止在全球范围内获得 64项授权专利

Active licensing discussions underway for human and veterinary use. 正在积极讨论人用和兽用产品的许可事宜

Large scale Colorectal Cancer, Lung Cancer and Blood Cancer studies underway globally 全球正在进行大规模的结直肠癌、肺癌

Initial COVID-19 trials and Sepsis study reported, longitudinal studies now underway, further NETs studies to be confirmed 报告了最初的COVID-19试验和败血症研究,目前正在进行纵 向研究,进一步的NETs研究尚待确认。

> Nu.Q® Capture could be an important sample preparation technology for liquid biopsy / Nu.Q®捕获技术可能是液体 活检的一项重要样本制备技术

Texas-based Volition Veterinary subsidiary beta launched Nu.Q® Vet Cancer Screening Test 总部位于德克萨斯州的Volition Veterinary子公司 推出Nu.Q®动物癌症筛查测试版



Commercial Strategy 商业策略

We believe that given the low-cost, accessible routine nature of our tests 我们相信,鉴于我们的检测成本低、方便获得的特点









will eventually be used throughout the world.

最终将在全世界范围内使用。

Product Strategy 产品策略

We plan to develop multiple products across a range of diseases falling into the following categories:我们计划针对以下类别的癌症开发多种产品:

Potential Use 潜在的用途	Frontline Human and Canine Screening Tests 一线人和犬筛 查测试	Triage Tests to improve sensitivity and/or specificity of existing tests分级测试以提高现有测试的敏感性和/或特异性	Aid to Diagnosis 辅助诊断	Disease Monitoring 疾病监测	Treatment Response 治疗反应
Subjects 对象	Asymptomatic Human and Canine Subjects 无症状的人和 犬对象	High Risk Subjects (For example, FIT positive, LDCT positive)高风险对象(例如,FIT阳性,LDCT阳性)。	Symptomatic human and canine Patients 有症状的 人类和犬类患者	Diagnosed human and canine Patients 已诊断出的人 类和犬类患者	Treated human and canine Patients接受治 疗的人类和犬 类患者
Potential Disease(s) 潜在的疾病	Most prevalent cancers (Ca) (Lung, Prostate, Colorectal, Breast, Non-Hodgkins Lymphoma, Canine Lymphoma, Canine hemangiosarcoma) 最常 见的癌症(肺、前列腺、结直	Lung Ca, Prostate Ca, Colorectal Ca 肺癌、前列腺癌、 结直肠癌	Blood Ca, Colorectal Ca血癌, 结直肠癌 Canine Blood Cancers犬类血癌	COVID-19, Sepsis, Cancers 新冠病毒、败 血症、癌症	COVID-19, Sepsis, Cancers 新冠病毒、败 血症、癌症

PLUS Licensing & Collaboration Opportunities 加上许可和合作 机会



肠、乳腺、非霍奇金淋巴瘤、 大类淋巴瘤、大类血管肉瘤)





KEY DIFFERENTIATOR - Intellectual Property

nu·a

关键的区别 - 知识产权

- Our patent portfolio is growing 我们的专利组合正在增长1.
 - 28 patent families / 28个专利家族
 - 10 patents granted in the U.S. 在美国获得了10项专利
 - 14 patents granted in the Europe 在欧洲获得14项专利
 - 42 additional patents granted worldwide in growing IP portfolio 全球范围内不断增长的知识产权,获授42项专利
 - 93 patents pending worldwide 全球有93项专利正在申请中
- Protection expected through or least to 2031 for products including animal diagnostics预计产品保护至少到2031年,包括动物诊断


Further Breakthrough Patents Ongoing 不断取得突破性专利

1. Sagittarius IP, patents as of 31 March, 2021 截止2021年3月31日专利



Nu.Q® - The basic concept (across species) Nu.Q™ -基本概念(跨物种)






The genome is **3 billion** base pairs. If un-coiled it would measure 5 feet long. Every 150 base pairs of DNA are wrapped around a nucleosome to form a DNA-Nu complex. 基因组是**30** 亿个碱基对。如果不卷曲,则其长度为5英尺。每隔150个碱基对的DNA包裹在核小体周围,形成DNA-Nu复合体。

Each individual bead is called a **nucleosome**. 每个单独的珠子称为**核小体**。

Nucleosomes consist of DNA and histone proteins. Histones and DNA are subjected to a variety of **epigenetic modifications.** 核小体由**DNA**和组蛋白组成。组蛋白和**DNA**受到多种表观遗传修饰。

Cancer leads to cell death which results in fragmentation and release of nucleosomes into the blood. 癌症导致细胞死亡,从而导致核小体碎裂并释放到血液中。

Nu.Q™ assays quantifies nucleosomes from different origins e.g. cancer versus healthy using simple immunoassay, mass spectrometry and/or sequencing. / Nu.Q™分析可量化来自不同来源的核小体,例如使用简单的免疫测定、质谱和/或测序技术可将癌症与健康进行比较。



Volition® 2021

Regulatory Approach 监管程序



- Commercialization of our future products in the clinical IVD market (e.g. for patient diagnosis in hospitals, clinics, etc.) requires government approval我们的产品未来在临床体外诊断市场商业化(例如在医院、诊所等诊断患者)需要政府批准。
 - CE Marking in Europe欧洲的CE认证
 - In Europe, our tests can be marketed after a declaration and marking that the test conforms to the essential requirements of the relevant European Directive or CE Marking. The CE Mark is also recognized in certain Asian territories, including India, for the private payer market.在欧洲,我们的检测在确定符合相关欧洲指令的基本要求或CE 标记后可以上市。CE认证在包括印度在内的某些亚洲地区的私人支付者市场也得到了认可。
 - FDA approval in the United States在美国获得FDA批准
 - In the United States, we anticipate that our tests will have to be cleared through the FDA's premarket notification or 510(k), process or its premarket approval, or PMA, process.在美国,我们预计我们的检测将必须通过美国食品药物管理局的上市前通知或510(k)程序或其上市前批准或PMA程序获得批准。
 - The determination of whether a 510(k) or a PMA is necessary will depend in part on the proposed indications for use and the FDA's assessment of the risk associated with the use of the IVD for a particular indication. 确定是510(k)还是PMA将 部分取决于拟议的使用适应症以及FDA对与特定适应症使用IVD相关的风险评估。
 - Chinese Food and Drug Administration (CFDA) approval in China similar to the US FDA 在中国需要中国食品药品监督管理局(CFDA) 批准 与美国FDA类似

Launch Sequence 启动顺序

• Largely determined by regulatory hurdles – aim to launch in 很大程度上取决于监管障碍,目标市场是:

EUROPE ASIA USA and beyond 欧洲、亚洲、美国和其他地区

• Aggressively seeking licensing opportunities worldwide 积极寻求全球的许可机会

Keeping things Simple – Nu.Q® H3.1 assay 问题简单化- Nu.Q® H3.1 检测



Continue to develop other assays to form panels for more complex cancers (colorectal, lung etc) 继续开发其他检测方法,形成更复杂的癌症(结肠直肠癌、肺癌等)的检测组合。

- CE Mark achieved 取得CE认证
- Highest ever single assay results in many studies 在许多研究中取得了有史以来最高的单项检测结果
- Will utilize for 将用于;
 - Nu.Q® Vet Cancer Screening Test / Nu.Q®动物癌症筛查检测
 - Blood Cancer Studies 血癌研究
 - COVID-19 and NETosis Studies (E.g. Sepsis, Influenza) 新冠病毒和NETosis研究(如败血症、流感)



Introducing the Nu.Q[®] Vet Cancer Screening Test 介绍Nu.Q[®]动物癌症筛查检测

Significant Market Opportunity 巨大的市场机会

- 38% of U.S. Households have a dog –
 the highest rate since measuring began
 in 1982 / 38%的美国家庭养狗 自1982年
 开始记录以来最高水平 ¹
- Approx. 77 million dogs 大约7700万只狗¹
- Target 7 yrs old+ dogs approx. 20
 million dogs目标是7岁以上的狗,大约
 2000万只
- 83% of dogs visit Veterinarian at least once a year / 83%的狗每年至少去一次兽医 诊所
- 75% of visits are for routine / preventative care / 75%的就诊是为了常规护理/预防性护理。

Volition iii Veterinary Veterinary

Approx. **6** million cancer diagnoses in DOGS in the U.S. each year 每年美国进行大约**600**万次狗的癌症诊断²

Approx. **1.66** million cancer diagnoses in HUMANS in the U.S. each year每年美国进行大约**166万**次人的癌症诊断³

than 3.5X / 3.5倍以 上

More

VS

1. 2017-1018 AVMA Pet Ownership and Demographics SourceBook / 2017-1018宠物所有权和 数量统计资料手册

2. https://fetchacure.org/resource-library/facts//

Our Product Proposition我们产品的定位



- The Nu.Q® Vet Cancer Screening Test is positioned for use in the annual health check of older dogs (those that are seven years and older) and may also be a complementary test for younger dogs at high risk for developing cancer in their lifetimes such as Golden Retrievers / Nu.Q®动物癌症筛查检测被定位为用于老年狗(7岁及以上)的年度健康检查和高度疑似癌症的情况,也可以是对金毛寻回犬等一生中患癌风险较高的年轻狗的一种补充检测。
- It is a **simple**, **low-cost**, **easy to use** ELISA based screening blood test which will help streamline the diagnostic process for up to $1/3^{rd}$ of malignancies in dogs namely Lymphoma and Hemangiosarcoma. 它是一种简单、低成本、易于使用的基于ELISA的血液筛查检测,将有助于简化多达1/3的狗恶性肿瘤的诊断过程,即淋巴瘤和血管肉瘤。
- In a study of over 330 dogs, at **100**% specificity, the Nu.Q® Vet Cancer Screening Test identified **74**% of lymphomas and **89**% of hemangiosarcoma versus control 在一项针对330多只狗的研究中,在**100**%的特异性下,与对照组相比,Nu.Q®动物癌症筛查检测确定了**74**%的淋巴瘤和**89**%的血管肉瘤^{1,2}.
- It is available from the GI Lab at Texas Results due 3-5 business days 在德克萨斯州的GI Lab 可进行检测, 3-5个工作日可出结果


CHARACTERIZING CIRCULATING NUCLEOSOMES IN THE PLASMA OF DOGS WITH LYMPHOMA, Dolan, Christopher; Wilson-Robles H; Miller T; Jarvis J; Terrell J; Dewsbury N; Herzoo. M; Kelly T; Byoott. T; Nichel, G

CHARACTERIZING CIRCULATING NICLEOSOMES IN THE PLASMA OF DOGS WITH HEMANGIOSARCOMA, Wilson-Robles H; Miller T; Jarvis J; Terrell J; Dewsbury N; Herzog M; Kelly T; Hardat N; Turatsinze JV; Michel, G



Nu.Q® Vet Cancer Screening Test has High Specificity and Sensitivity / Nu.Q®动物癌症筛查检测有很高的特异性和敏感性





LYMPHOMA, Dolan, Christopher: Wilson-Robles H: Miller T: Jarvis J: Terrell J: Dewsbury



X A S A & M UNIVERSITY

HEMANGIOSARCOMA, Wilson-Robles H: Miller T: Jarvis J: Terrell J: Dewsbury N: Herzog M: Kelly T; Hardat N; Turatsinze JV; Michel, G

Nu.Q® Vet Cancer Screening Test Launch Plan Nu.Q®动物癌症筛<u>查检测启动计划</u>



BETA Launch (Texas) 测试 启动(德克萨斯州)

- Real World Learnings 现实世界的经验
- Test out Marketing Mix测试营销组合
- Showcase our product展示我们的产品

Next Steps下一步

- Currently conducting active licensing discussions including some of the biggest global veterinary companies目前正在进行积 极的许可讨论,包括一些全 球最大的兽药公司
 - U.S. National Launch美国全国启动
- International Beta Launches
 (Asia & Europe) 国际测试版
 启动(亚洲和欧洲)

Product Development产品开 发

- Additional cancers added to the Cancer Screening Wellness Test癌症筛查健 康测试中增加癌症种类
- Treatment Response Monitoring治疗反应监测
- Disease Monitoring疾病监

Point of Care Test护理点检测







What is NETosis? 什么是NETosis?




- During infection, white cells migrate to the infected tissue to engulf invading pathogens and to produce antibodies against them. 在感染期间,白细胞迁移到受感染的组织,吞噬入侵的病原体并产生针对它们的抗体。
- In addition, white cells called neutrophils unwind their chromosomes and eject chromatin material, consisting of strings of nucleosomes, out of the cell to form NETs (Neutrophil Extracellular Traps).此外,被称为中性粒细胞的白细胞展开其染色体,并将由成串的核小体组成的染色质材料弹出细胞,形成NET(中性粒细胞胞外陷阱)。
- Bacteria and viruses become trapped in the NETs and are killed by cytotoxic proteins.细菌和病毒被困在NETs中,并被细胞毒性蛋白杀死。
- However, excessive production of NETs can damage the tissue and lead to the formation of potentially dangerous minute blood clots called microthrombi.然而,NETs的过度生产会损害组织,并导致形成潜在的危险的微小血块,即微血栓。

The ejected NETs can be measured using Volition's Nu.Q® nucleosome assays. 喷出的NETs可以用Volition的Nu.Q®核小体检测法进行测量。

What is NETosis? 什么是NETosis?





The role of NETosis / NETosis的作用



- Inappropriate inflammatory response 不适当的炎症反应
- Massive ejection of NETs (made up of nucleosomes) into the blood by white blood cells 白细胞将NETs (由核小体组成) 大量射入到血液中
- Causes damage to the lungs导致对肺部的损害
- Cause of death in many disease states 许多疾病状态下的死亡原因
 - COVID-19 新冠病毒
 - Influenza 流感
 - Sepsis 败血症
 - And many others...... 等等

Have formed a Nu.Q® NETs team to focus development program. 组建了一个Nu.Q® NETs团队,专注于开发活动

COVID-19 Product Development

治疗新冠病毒产品的开发



- The preliminary study results demonstrated the Area Under the Curve (AUC) for a single Nu.Q[®] assay was **98.7%** PCR positive COVID patients versus control subjects 初步研究结果表明,单个Nu.Q™检测的曲线下面积(AUC)与对照组相比,新冠病毒患者PCR阳性**98.7%**。
- To date we have now tested two independent cohorts of COVID-19 positive patients with quantitative nucleosome immunoassays and found that迄今为止,我们已经通过定量核小体免疫测定法对两个独立的COVID-19阳性患者组群进行了测试,发现1.
 - nucleosomes were highly elevated in plasma of severe COVID-19 patients 重症COVID-19患者血浆 中核小体大幅升高
 - importantly, histone 3.1 variant increased with disease severity.重要的是,组蛋白3.1变体随疾病严重程度而增加
- Given that the highest levels of nucleosomes were found in patients requiring artificial ventilation or extracorporeal oxygenation, these data imply that Nu.Q could serve as a guiding biomarker for disease severity in COVID-19 positive patients.鉴于在需要人工通气或体外充氧的患者中发现了最高水平的核小体,数据表明Nu.Q可以作为COVID-19阳性患者疾病严重程度的指导性生物标志物。

^{1. &}lt;a href="https://www.frontiersin.org/articles/10.3389/fmolb.2021.600881/full">https://www.frontiersin.org/articles/10.3389/fmolb.2021.600881/full Circulating Nucleosomes as Potential Markers to Monitor COVID -19 Disease Progression. Etienne Cavalier, Julien Guiot, Katharina Lechner, Alexander Dutsch, Mark Eccleston, Marielle Herzog, Thomas Bygott, Adrian Schomburg, Theresa Kelly, Stefan Holdenrieder

SEPSIS Product Development 败血症产品开发



- Animal Study to monitor treatment response to Santersus' developmental plasmapheresis treatment 监测Santersus开发的血浆疗法的治疗反应的动物研究
- Demonstrated that Nu.Q® is an effective method for monitoring Santersus' highly selective plasmapheresis treatment targeting Neutrophil Extracellular Traps ("NETs") in sepsis 证明了Nu.Q®是一种有效的方法,可以监测Santersus针对败血症中的中性 粒细胞外陷阱("NETs")的高选择性血浆注射疗法。1
- Santersus has already begun the next phase of studies that are also using Volition's Nu.Q® assays to monitor treatment response, including their first human trial. Santersus已经开始了下一阶段的研究,这些研究也使用Volition的Nu.Q®检测方法来监测治疗反应,包括他们的第一个人体试验。

^{1.} Therapeutic Removal of NETs from Blood in a Pig Model of Sepsis. E-ISFA conference A. Aswani3, 2, D. Genkin2, P. Skorup 4, J. Micallef 1, M. Wargnies 1, R. Varsebroucq 1, M. Lipcsey

Product Development 产品开发



- A number of studies underway at leading hospitals to test the use of Nu.Q® technology in many ways 领先的医院正在进行许多研究,以测试Nu.Q®技术在许多方面的应用;
 - Diagnostic aid 诊断辅助
 - Disease monitoring 疾病监测
 - Treatment Response Monitoring 治疗反应监测
 - Companion diagnostic 伴随诊断
 - We have filed a novel patent for the utilization of our Nu.Q® epigenetic platform in this area 我们已经为我们的Nu.Q®表观遗传学平台在这一领域的应用申请了一项新专利。
 - If we continue to see positive results, we aim to have a CE-marked product available on multiple platforms in 2021如果我们继续看到积极的结果,我们的目标是在2021年在多个平台上推出有CE认证的产品。

Cancer in Humans 人类癌症

The Market Opportunity (Cancer) 市场机会(癌症)

- Cancer is one of the leading causes of death worldwide, accounting for around **9.5 million** annual deaths globally. 癌症是全世界的主要死因之一,在全球每年引起约**950万**人死亡。
- There are over 18 million new cases of cancer diagnosed each year and given the aging population this is expected to **grow rapidly** to over 29.5 million new cases annually by 2040.每年有超过1800万个新诊断出的癌症病例,鉴于人口老龄化,预计到2040年这一数字将迅速增长到每年超过2950万个新病例。
- Currently, in the United States there are more than three new cases of cancer diagnosed and one person dies of a cancer-related death *every minute.*目前,在美国每分钟就有超过三个新诊断出的癌症病例,一个人死于癌症相关的疾病。
- Statistically, the chances of surviving cancer are greatly improved by *early* detection and treatment.据统计,通过早期发现和治疗,癌症的存活几率大大增加。
- However, there are currently very few blood tests for diagnosis of cancer in common clinical use.然而,目前在临床上普遍使用的诊断癌症的血液检测非常少。

We believe that early, non-invasive, accurate cancer diagnosis remains a significant unmet medical need and a significant commercial opportunity. 我们相信,早期、无创、准确的癌症诊断仍然是一个未得到满足的重大医疗需求和一个巨大的商业机会。

Cancers: Proof of concept data of product grade Nu.Q®assays (on plates) 癌症: 产品级Nu.Q™检测的概念验证数据(在板上)

nu-a

In a Lung cancer cohort

(76 subjects), a single Nu.Q assay detected lung cancer, including *stage I* lung cancer. The AUC for this single assay was 85%

(cancer vs healthy)在一个肺癌组群(76名受试者),单项 Nu. Q分析检测到肺癌,包括*I期* 肺癌。

该单一测定的AUC为85%(癌症

vs**健康)**

In a second
Confirmatory Lung
cancer cohort
(152 subjects), the same
single Nu.Q assay also
detected lung cancer with
an AUC of 79% (cancer vs
healthy)在第二个确诊的肺癌组群(152名受试者),
同一项Nu.Q分析也检测肺癌
AUC为79%(癌症vs健康)

In an interim analysis of a subset from the NTU Lung Lung Cancer Study
Nu.Q could help identify noncancerous nodules following a LDCT scan thereby reducing unnecessary biopsies by as much as 32%. 在对NTU肺癌研究的一个子集的中期分析中,Nu.Q可以帮助识别LDCT扫描后的非癌结节,从而减多达32%的不必要的活检

In a Blood

cancer cohort (54 subjects) the same Nu.Q assay detected blood cancer with an AUC of 91% (cancer vs healthy)在一个血液癌组群(54名受试者),同一Nu.Q分析检测到的血液癌的AUC为91%(癌症vs健康)

In a Colorectal

cancer cohort (123 subjects) the same Nu.Q assay detected colorectal cancer with an AUC of **72%** while a two-assay panel had an AUC of **84%** (cancer vs healthy)在一个结肠直肠癌组群(123名受试者),相同的Nu.Q分析检测到的结直肠癌的AUC为**72%**,而两项分析的AUC为**84%**(癌症vs健康)

ONGOING STUDIES

正在进行的研究

NTU CRC 7000+ subjects 对象 EDRN CRC 7000 subjects 对象 NTU Lung 1200 subjects 对象 U.S. DXO NHL 1500 subjects 对象

AUC is Area Under the Curve. The AUC is an accepted measure of the effectiveness of an assays whereby 100% is the most accurate. / AUC是曲线下的面积。AUC是测定有效性的公认标准,其中100%是最准确的。

Introducing介绍......discover

- Sale of Research Use Only Assays销售仅供研究使用的检测方法
- In-house Service provision of sample processing for external parties such as pharmaceutical companies, biotech companies and academic researchers.为制药公司、生物技术公司和学术研究人员等外部人士提供内部服务,进行样品处理。
- Thus far the projects we are handling through our Nu.Q® Discover service involve exploring the use of our assays to monitor the efficacy of our customers' therapeutics in development for cancer, NETosis, and other serious and/or chronic diseases in both pre-regulatory and regulatory trials.到目前为止,我们通过Nu.Q® Discover服务处理的项目涉及探索使用我们的检测方法来监测我们的客户正在开发的治疗癌症、NETosis和其他严重和/或慢性疾病的疗效,包括监管前和监管试验。

Milestones 里程碑



- We will focus on driving revenue in the coming quarters where possible during the pandemic in 4 key areas:在未来几个季度,我们将专注于在四个关键领域推动收入增长:
 - Nu.Q® Vet products, both thorough product launched and licensing. / Nu.Q®动物产品,启动产品和许可
 - Disease monitoring tests (e.g. Nu.Q[®] NETs for COVID-19, Sepsis),疾病检测测试(例如,Nu.Q[®] NETs,新冠病毒、败血症)
 - Nu.Q® Discover processing samples at Silver One using our Nu.Q Discovery assays, and 使用我们的Nu.Q Discovery检测在Silver One处理样品
 - Licensing of our technology for others to commercialize in both humans and animals.将我们的技术授权给他人,以便在人类和动物身上进行商业化

Please watch out for updates on all these areas.

请关注我们在所有这些领域的最新进展

Key Financials 关键财务数据

NYSE American: VNRX

Market Cap: \$165m 市值: \$1.65亿*

52-week range / 52周波动区间: \$2.78-\$6.67*

Monthly Burn: Approx. \$2m 月度花费:约\$200万**

Cash-on-hand: ~\$33.1m 手头现金: ~\$3310万 **



* As of May 7, 2021 截 止2021年5月7日

**As of March 31, 2021 截止2021年3月31日

Becoming a *leading* epigenetics company

成为一家领先的表观遗传学公司

Significant milestones throughout 2021 / 2021 年全年多个重大里程碑事件....

....Exciting times 激动人心的时刻!!

Executive Team



Dill Faulkes PhD, Executive Chairman - Dill Faulkes has over 30 years of entrepreneurial and managerial experience as the founder and CEO of several software companies within the United Kingdom and the United States. As the Founder and one of the Benefactors of the Dill Faulkes Educational Trust, a UK registered charity, Dill also focuses on charitable activities.



Cameron Reynolds MBA, President & Group Chief Executive Officer - Cameron has extensive experience in the management, structuring, and strategic planning of start-up companies and hasheld positions including Chief Executive Officer, Chief Financial Officer, and Non- Executive Director of public and private enterprises. Cameron was educated at the University of Western Australia receiving both a B.Com, and an MBA.



Terig Hughes, Group Chief Financial Officer – Terig is a seasoned finance professional with over twenty-five years of accounting, finance and business management experience gained through an international career spanning US, Europe and Asia. Terig received a Bachelor's degree in Accounting and Law from De Montfort University, Leicester, UK.



Gaetan Michel PhD, Chief Operating Officer – Gaetan has over 15 years' project management, manufacturing and operational experience at AAT (Advanced Array Technology), EAT (Eppendorf Array Technology), KitoZyme a global manufacturer of biopolymers of fungal origin and latterly Volition. Gaetan was educated at the University of Namur, Belgium receiving both a Bachelor of Science and a PhD.



Louise Batchelor, Chief Marketing and Communications Officer - Lou has more than 25 years of marketing, sales and leadership experience. Formerly Lou worked in various roles at Reckitt Benckiser including roles in Paris and New York. Sheholds a BA in Business Studies from Sheffield Hallam University.

高管团队



Dill Faulkes博士,执行董事会主席——Dill Faulkes作为英国和美国多家软件公司的创始人和首席执行官,拥有超过30年的创业和管理经验。作为英国注册慈善机构Dill Faulkes Educational Trust的创办人和受益人之一,Dill还致力于慈善活动。



Cameron Reynolds,工商管理硕士,总裁兼集团首席执行官——Cameron在新兴公司的管理,组织和战略规划方面拥有丰富的经验,并在公共和私营企业担任首席执行官、首席财务官以及非执行董事。 Cameron在西澳大利亚大学获得商学学士和工商管理硕士学位。



Terig Hughes, 集团首席财务官-Terig是一位经验丰富的财务专家,拥有超过25年的会计、财务和商业管理经验,其国际职业生涯横跨美国、欧洲和亚洲,在英国莱斯特的德蒙福特大学获得了会计和法律的学士学位。



Gaetan Michel博士, 首席运营官 – Gaetan有超过15年的项目管理、生产和运营经验,曾任职于AAT (先进阵列技术)、EAT (Eppendorf阵列技术)、KitoZyme(全球真菌源生物聚合物制造商),后来入职Volition,曾在那慕尔大学学习,获得了理学学士和博士学位。



Louise Batchelor, 首席营销和传播官-Lou拥有超过25年的营销、销售和领导经验。曾在Reckitt Benckiser担任过各种职务,包括在巴黎和纽约任职。拥有谢菲尔德哈兰大学的商业研究学士学位。

Executive Team



Jake Micallef PhD MBA, Chief Scientific Officer - Jake is an experienced scientist with expertise in research and development and in the management of biotechnical companies, including manufacturing and establishing operations. He received his BSc and a PhD in Physical Chemistry from King's College London. In addition, he received his MSc in Chemical Pathology, and an MBA from Imperial College Management School.



Jasmine Kway PhD, Chief Executive Officer, Singapore Volition - Jasmine has a proven track record in achieving positive business results by developing strategic business alliances and identifying new markets. She has successfully commercialised and expanded companies into the Asian markets. Jasmine has a B.Eng and a PhD in Oceanography from the National University of Singapore.

Tom Butera DVM, Chief Executive Officer of VVDD – Tom is a Doctor of Veterinary Medicine with more than 40 years of experience in equine and small animal health in private practice, as well as extensive work in both business development and management of veterinary companies. He earned his Doctor of Veterinary Medicine from the University of Missouri Veterinary School, going on to serve as an Assistant Professor at Tufts University Veterinary School. Tom is an honorary member of the American Veterinary Medical Association and a licensed veterinarian in the Commonwealth of Massachusetts.




Heather Wilson-Robles DVM, Chief Medical Officer of VVDD – Heather is a well-established veterinary medical oncologist specializing in canine models of human cancer. Her research over the past 12 years has focused on improving canine models of pediatric and adult cancers and translating these findings to the mutual benefit of both species. Her basic research focuses on the identification and targeting the tumor initiating cells in osteosarcoma, melanoma and mammary/breast cancers in both canines and humans.



Gael Forterre MBA, Chief Commerical Officer - Gael has extensive experience investing in and scaling fast growing companies and is a board member of Ucroo Inc. and Article22. Gael started his career as a hedge fund analyst in Paris and worked in a number of investment banking and trading roles over ten plus years. Gael received a master's in finance from Sorbonne Paris I and a double MBA from Columbia Business School and the London Business School.

高管团队



Jasmine Kway博士, Singapore Volition首席执行官 - Jasmine在建立积极的商业成果方面有着良好的履历,通过建立战略性商业联盟和确定新市场来取得积极的商业成果。成功地将公司商业化并扩展到亚洲市场。拥有新加坡国立大学的海洋学学士学位和博士学位。

Tom Butera DVM, VVDD首席执行官-汤姆是一名兽医博士,在马匹和小动物健康方面有超过40年的私人执业经验,并在兽医公司的业务发展和管理方面有广泛的工作经验,在密苏里大学兽医学院获得了兽医学博士学位,随后在塔夫茨大学兽医学院担任助理教授,是美国兽医协会的荣誉会员,也是马萨诸塞州联邦的执业兽医。

Heather Wilson-Robles DVM, VVDD首席医学官 – Heather是一位知名的兽医医学肿瘤学家,专门研究人类癌症的犬模型。在过去的12年中,专注于改善小儿和成人癌症的犬模型研究,并将这些发现转化为两种物种的共同利益。基础研究专注于鉴定和靶向犬和人的骨肉瘤、黑色素瘤和乳腺/乳腺癌中的肿瘤起始细胞。

Gael Forterre,工商管理硕士,首席商务官-Gael在投资和扩大快速增长的公司方面有丰富的经验,是Ucroo公司和Article22的董事会成员,其职业生涯始于在巴黎担任对冲基金分析师,在十多年的时间里,曾在多家投资银行和交易岗位上工作,拥有巴黎第一大学的金融硕士学位,以及哥伦比亚商学院和伦敦商学院的双料工商管理硕士学位。



Executive Team



Jason Terrell MD, Chief Medical Officer & Chief Executive Officer of Volition America, Inc. - Jason has expertise in clinical medicine and in laboratory diagnostics in the areas of business development, clinical trials, regulatory affairs and commercialization strategies. He was educated at Hardin-Simmon University where he graduated Summa Cum Laude, also receiving the Holland Medal of Honor. He received his MD from the University of Texas Medical School an affiliate of the MD Anderson Cancer Center.



Mark Eccleston PhD, MBA Chief Technology Officer - Mark is an enthusiastic and passionate biotechnology entrepreneur with over 20 years experience in the sector. He holds a PhD in Polymer Chemistry for biomedical applications and gained an MBA (entrepreneurship) from the University of Dundee in 2008.



Marielle Herzog PhD, Research & Development Director – Marielle is an epigeneticist with nearly 15 years research experience at the Institute of Genetics and Molecular and Cellular Biology (IGBMC), Strasbourg, the Laboratory of Cancer Epigenetics, Free University of Brussels and as the R&D director at Volition. She manages a team of project managers and coordinates several external academic collaborations as well as outsourced commercial R&D and clinical programs.



Theresa Kelly PhD, Chief Scientific Officer of Volition America, Inc. -Terry has over 10 years of experience in Epigenetics including developing novel technologies and seeing them through to commercialization. She previously was the R&D Director at Active Motif and the Global leader for custom assays and services and Agena Bioscience. She received her PhD from UCLA and did Post-doctoral training at USC's Norris Cancer Center where she studied epigenetic regulation in Cancer.



Rod Rootsaert LLB, Corporate Secretary - Rod is an experienced legal and corporate secretary with over ten years' experience in providing corporate, legal and administrative services to start-up companies. He previously served as corporate secretary for several junior mining companies in the United Kingdom. Rod received a LLB from the University of Western Australia.



Scott Powell PhD, EVP, Investor Relations & CFO of Volition America, Inc. - Scott has over 20 years of experience in the U.S. capital markets and investor relations. Scott worked for several years as an investment banker. He earned his B.S. in Business Administration from Bryant University and his MA and PhD degrees from Brown University.

高管团队



Jason Terrell医学博士,Volition America, Inc. 首席医学官兼首席执行官一 Jason在业务发展、临床试验、法规事务和商业化策略领域的临床医学和实验室诊断方面拥有专业知识,在哈丁-西蒙大学受教育,获得拉丁文学位荣誉,并获得了荷兰荣誉勋章,从德克萨斯大学医学院安德森癌症中心的附属机构获得医学博士学位。


Mark Eccleston博士,工商管理硕士,首席技术官 - Mark是一位热情的生物技术企业家,在该领域拥有20多年的经验,拥有生物医学应用高分子化学博士学位,并于2008年获得了邓迪大学的工商管理硕士(创业学)学位。



Marielle Herzog博士,研发总监 – Marielle是表观遗传学家,在斯特拉斯堡的遗传与分子和细胞生物学研究所(IGBMC)、布鲁塞尔自由大学癌症表观遗传学实验室拥有近15年的研究经验,并担任Volition研发总监,管理着一个由四名项目经理组成的团队,并协调数次外部学术合作以及外包的商业研发和临床计划。



Theresa Kelly博士,Volition America, Inc.首席科学官一Terry在表观遗传学领域拥有10多年的经验,包括开发新技术并实现商业化,曾担任Active Motif的研发总监,以及定制分析和服务以及Agena Bioscience的全球负责人,获得了加州大学洛杉矶分校(UCLA)博士学位,并在南加州大学诺里斯综合癌症中心(Norris Cancer Center)进行了博士后培训,研究了癌症的表观遗传调控。



Rod Rootsaert, 法学士, 工商秘书 - Rod是经验丰富的法律和公司秘书, 在为初创公司提供公司、法律和行政服务方面拥有十多年的经验, 曾在英国的几家初级矿业公司担任公司秘书。Rod获得了西澳大利亚大学的法学学士学位。







Thank you for your interest in Volition 感谢您关注Volition

For more information please visit our website and watch our Corporate Video at www.volition.com or email mediarelations@volition.com

欲了解更多信息,请访问我们的网站<u>www.volition.com</u>观看我们公司的视频,或发送邮件 mediarelations@volition.com